Latest Regulatory News

St Barbara Limited reported a $52 million underlying loss for FY25, driven by investments in its Simberi Expansion Project and operational challenges. The company classified its Atlantic operations as discontinued, recognizing a $38 million impairment, while completing a $100 million capital raise to support growth.

Mount Ridley Mines Limited has announced a pro-rata entitlement offer to raise up to $596,842, accompanied by free attaching options, alongside a $234,000 placement aimed at funding key exploration projects and working capital.

Heartland Group Holdings Limited reported an underlying NPAT of NZD 46.9 million for FY2025, meeting guidance, while setting ambitious growth and efficiency targets for FY2026.

Kaili Resources Limited has resumed trading on the ASX following a suspension triggered by regulatory queries. The company’s prompt response to ASX concerns has cleared the way for its securities to re-enter the market.

Kaili Resources has officially confirmed a change of control with Mr Jianzhong Yang now holding over 60% of shares, alongside a significant board reshuffle. The company remains focused on advancing its rare earth elements exploration in South Australia.

Artrya Limited reported a 17.2% increase in net loss to $16.4 million for FY25, while achieving FDA clearance and launching its AI-driven Salix platform in the U.S. market. The company also secured key commercial partnerships in Australia and raised $20 million in equity funding.

Astron Corporation Limited is set to redomicile from Hong Kong to Australia through a scheme of arrangement, creating a new Australian parent company, Aus NewCo. This move aims to align the corporate structure with its Australian assets and simplify shareholder voting.

Euroz Hartleys Group Limited reported a robust 87.7% increase in net profit for FY25, driven by growth across brokerage, underwriting, and wealth management. The company declared a fully franked full-year dividend of 5.5 cents per share, reflecting confidence in its operational leverage and balance sheet strength.

The Takeovers Panel has declined to investigate alleged breaches related to Yowie Group’s recent share placement and funding arrangements, finding no material impact on company control or disclosure issues.

Prescient Therapeutics reported an 11.1% reduction in net loss for FY2025, progressing its lead candidate PTX-100 into Phase 2a trials with FDA Fast Track and Orphan Drug designations, supported by a recent $9.8 million capital raise.

Xstate Resources has received pre-approval to acquire a 51% stake in the Diona project, setting the stage for drilling operations and ASX trading resumption by late September.

Astron Corporation has completed its redomicile from Hong Kong to Australia, launching Astron Limited (Aus NewCo) as the new ASX-listed parent company with a 2-for-1 share consolidation.